ID   IGROV-1/CP
AC   CVCL_IQ21
SY   IGROV-1-CP; IGROV1CP
DR   cancercelllines; CVCL_IQ21
DR   PRIDE; PXD003668
DR   Wikidata; Q54897385
RX   PubMed=16319398;
RX   PubMed=23913215;
RX   PubMed=27561551;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Lys654Serfs*47 (c.1961delA); ClinVar=VCV000037438; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Lys1108Argfs*11 (c.3323delA) (p.Gln1107fs) (c.3320delA); ClinVar=VCV000225716; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg38Cys (c.112C>T); ClinVar=VCV000376493; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Ter1069TrpinsLysAspAsn (c.3207A>G); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.955_958delACTT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Val654Cysfs*4 (c.1959delA); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gly231Alafs*10 (c.692delG); ClinVar=VCV001756201; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Leu495Pro (c.1484T>C); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Leufs*59 (c.267dupC) (c.267_268insC); ClinVar=VCV000634762; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Cys (c.377A>G); ClinVar=VCV000458541; Zygosity=Heterozygous (from parent cell line).
CC   Omics: Deep proteome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7979; Ovarian endometrioid adenocarcinoma
DI   ORDO; Orphanet_454723; Endometrioid carcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1304 ! IGROV-1
SX   Female
AG   47Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 05-10-23; Version: 17
//
RX   PubMed=16319398; DOI=10.1074/mcp.M500140-MCP200;
RA   Stewart J.J., White J.T., Yan X.-W., Collins S.J., Drescher C.W.,
RA   Urban N.D., Hood L.E., Lin B.-Y.;
RT   "Proteins associated with cisplatin resistance in ovarian cancer cells
RT   identified by quantitative proteomic technology and integrated with
RT   mRNA expression levels.";
RL   Mol. Cell. Proteomics 5:433-443(2006).
//
RX   PubMed=23913215; DOI=10.1007/978-1-62703-547-7_12;
RA   Li L.-S., Liu J., Yu W., Lou X.-Y., Huang B.-D., Lin B.-Y.;
RT   "Deep transcriptome profiling of ovarian cancer cells using
RT   next-generation sequencing approach.";
RL   Methods Mol. Biol. 1049:139-169(2013).
//
RX   PubMed=27561551; DOI=10.1038/ncomms12645;
RA   Coscia F., Watters K.M., Curtis M., Eckert M.A., Chiang C.-Y.,
RA   Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M.;
RT   "Integrative proteomic profiling of ovarian cancer cell lines reveals
RT   precursor cell associated proteins and functional status.";
RL   Nat. Commun. 7:12645.1-12645.14(2016).
//